Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
received:
13
12
2023
accepted:
02
03
2024
medline:
19
3
2024
pubmed:
19
3
2024
entrez:
19
3
2024
Statut:
aheadofprint
Résumé
Therapeutic neutralization of Oncostatin M (OSM) causes mechanism-driven anemia and thrombocytopenia, which narrows the therapeutic window complicating the selection of doses (and dosing intervals) that optimize efficacy and safety. We utilized clinical data from studies of an anti-OSM monoclonal antibody (GSK2330811) in healthy volunteers (n = 49) and systemic sclerosis patients (n = 35), to quantitatively determine the link between OSM and alterations in red blood cell (RBC) and platelet production. Longitudinal changes in hematopoietic variables (including RBCs, reticulocytes, platelets, erythropoietin, and thrombopoietin) were linked in a physiology-based model, to capture the long-term effects and variability of therapeutic OSM neutralization on human hematopoiesis. Free serum OSM stimulated precursor cell production through sigmoidal relations, with higher maximum suppression (I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
West, N.R., Owens, B.M.J. & Hegazy, A.N. The oncostatin M-stromal cell axis in health and disease. Scand. J. Immunol. 88, e12694 (2018).
West, N.R. Coordination of immune-stroma crosstalk by IL-6 family cytokines. Front. Immunol. 10, 1093 (2019).
Chollangi, S., Mather, T., Rodgers, K.K. & Ash, J.D. A unique loop structure in oncostatin M determines binding affinity toward oncostatin M receptor and leukemia inhibitory factor receptor. J. Biol. Chem. 287, 32848-32859 (2012).
Dey, G. et al. Signaling network of oncostatin M pathway. J. Cell Commun. Signal. 7, 103-108 (2013).
Hermanns, H.M. et al. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. J. Immunol. 163, 6651-6658 (1999).
Sato, F., Miyaoka, Y., Miyajima, A. & Tanaka, M. Oncostatin M maintains the hematopoietic microenvironment in the bone marrow by modulating adipogenesis and osteogenesis. PLoS One 9, e116209 (2014).
Minehata, K. et al. Oncostatin M maintains the hematopoietic microenvironment and retains hematopoietic progenitors in the bone marrow. Int. J. Hematol. 84, 319-327 (2006).
Tanaka, M., Hirabayashi, Y., Sekiguchi, T., Inoue, T., Katsuki, M. & Miyajima, A. Targeted disruption of oncostatin M receptor results in altered hematopoiesis. Blood 102, 3154-3162 (2003).
Wallace, P.M., MacMaster, J., Rillema, J.R., Peng, J., Burstein, S.A. & Shoyab, M. Thrombocytopoietic properties of oncostatin M. Blood 86, 1310-1315 (1995).
Lee, M.J., Song, H.Y., Kim, M.R., Sung, S.M., Jung, J.S. & Kim, J.H. Oncostatin M stimulates expression of stromal-derived factor-1 in human mesenchymal stem cells. Int. J. Biochem. Cell Biol. 39, 650-659 (2007).
Mozaffarian, A. et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J. Immunol. 181, 7243-7253 (2008).
West, N.R. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat. Med. 23, 579-589 (2017).
Marden, G. et al. The role of the oncostatin M/OSM receptor β axis in activating dermal microvascular endothelial cells in systemic sclerosis. Arthritis Res. Ther. 22, 179 (2020).
Verstockt, S., Verstockt, B. & Vermeire, S. Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD). Expert Opin. Ther. Targets 23, 943-954 (2019).
Choy, E.H. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials. Arthritis Res. Ther. 15, R132 (2013).
Reid, J. et al. In vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody. Br. J. Clin. Pharmacol. 84, 2280-2291 (2018).
Denton, C.P. et al. Biological and clinical insights from a randomised phase II study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Rheumatology 62, 234-242 (2022).
Milligan, P.A. et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin. Pharmacol. Ther. 93, 502-514 (2013).
Fornari, C. et al. Understanding hematological toxicities using mathematical modeling. Clin. Pharmacol. Ther. 104, 644-654 (2018).
Friberg, L.E. & Karlsson, M.O. Mechanistic models for myelosuppression. Invest. New Drugs 21, 183-194 (2003).
Mangas-Sanjuan, V., Buil-Bruna, N., Garrido, M.J., Soto, E. & Trocóniz, I.F. Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules. J. Pharmacol. Exp. Ther. 354, 55-64 (2015).
Bender, B.C. et al. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother. Pharmacol. 70, 591-601 (2012).
Quartino, A.L., Friberg, L.E. & Karlsson, M.O. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest. New Drugs 30, 833-845 (2012).
Finch, C.A., Harker, L.A. & Cook, J.D. Kinetics of the formed elements of human blood. Blood 50, 699-707 (1977).
Cao, Y., Balthasar, J.P. & Jusko, W.J. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J. Pharmacokinet. Pharmacodyn. 40, 597-607 (2013).
Gibiansky, L., Gibiansky, E., Kakkar, T. & Ma, P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J. Pharmacokinet. Pharmacodyn. 35, 573-591 (2008).
Lledó-Garćia, R., Kalicki, R.M., Uehlinger, D.E. & Karlsson, M.O. Modeling of red blood cell life-spans in hematologically normal populations. J. Pharmacokinet. Pharmacodyn. 39, 453-462 (2012).
Hu, J. et al. Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo. Blood 121, 3246-3253 (2013).
Kuter, D.J. The biology of thrombopoietin and thrombopoietin receptor agonists. Int. J. Hematol. 98, 10-23 (2013).
Jelkmann, W. Regulation of erythropoietin production. J. Physiol. 589, 1251-1258 (2011).
Piva, E., Brugnara, C., Spolaore, F. & Plebani, M. Clinical utility of reticulocyte parameters. Clin. Lab. Med. 35, 133-163 (2015).
Bauer, R.J. NONMEM tutorial part II: estimation methods and advanced examples. CPT Pharmacometrics Syst. Pharmacol. 8, 538-556 (2019).
Khanna, D. et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 8, 963-974 (2020).
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Common Terminology Criteria for Adverse Events (CTCAE) Version 5 <https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm> (2017).
Choi, K. et al. Reference values of hematology, biochemistry, and blood type in cynomolgus monkeys from Cambodia origin. Lab. Anim. Res. 32, 46-55 (2016).
Wilson, J.L., Lu, D., Corr, N., Fullerton, A. & Lu, J. An in vitro quantitative systems pharmacology approach for deconvolving mechanisms of drug-induced, multilineage cytopenias. PLoS Comput. Biol. 16, e1007620 (2020).
Fornari, C. et al. Quantifying drug-induced bone marrow toxicity using a novel Haematopoiesis systems pharmacology model. CPT Pharmacometrics Syst. Pharmacol. 8, 858-868 (2019).
Chen, W. et al. A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor. J. Pharmacokinet. Pharmacodyn. 47, 163-182 (2020).
Friberg, L.E., Henningsson, A., Maas, H., Nguyen, L. & Karlsson, M.O. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J. Clin. Oncol. 20, 4713-4721 (2002).
Zhou, D. et al. Efficacy and safety exposure-response analyses of Olaparib capsule and tablet formulations in oncology patients. Clin. Pharmacol. Ther. 105, 1492-1500 (2019).
Gibiansky, L. & Frey, N. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. J. Pharmacokinet. Pharmacodyn. 39, 5-16 (2011).
Furqan, M., Mukhi, N., Lee, B. & Liu, D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res. 1, 5 (2013).
Shrestha, R.P. et al. Models for the red blood cell lifespan. J. Pharmacokinet. Pharmacodyn. 43, 259-274 (2016).
Zhang, H.-D. et al. Human erythrocyte lifespan measured by Levitt's CO breath test with newly developed automatic instrument. J. Breath Res. 12, 36003 (2018).
Mitlyng, B.L., Singh, J.A., Furne, J.K., Ruddy, J. & Levitt, M.D. Use of breath carbon monoxide measurements to assess erythrocyte survival in subjects with chronic diseases. Am. J. Hematol. 81, 432-438 (2006).
Weiss, G., Ganz, T. & Goodnough, L.T. Anemia of inflammation. Blood 133, 40-50 (2019).
Weiss, G. & Goodnough, L.T. Anemia of chronic disease. N. Engl. J. Med. 352, 1011-1023 (2005).
Macdougall, I.C., Roberts, D.E., Coles, G.A. & Williams, J.D. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin. Pharmacokinet. 20, 99-113 (1991).
Kuter, D.J. New thrombopoietic growth factors. Blood 109, 4607-4616 (2007).
van Besouw, N.M. et al. Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol. Dial. Transplant. 14, 2710-2713 (1999).